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Introduction
o Evidence shows the efficacy of
radiation therapy relies on
interferon (IFN) signaling.
o Radiotherapy (RT), in a type 1 IFNdependent manner , promotes
innate immune responses that
support an adaptive immune
response and anti-tumor immunity.
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Fig. 3 Relative mRNA expression for
IFNb1 and CCL5 in cells treated with
radiation and drugs.
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Results

Fig. 1 Role of Interferon-Beta (IFNb)

o We hypothesized that RORα
and Rev-erbα work together
with radiation to augment type
1 IFN production.
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o Direct administration of interferon
to patients has adverse outcomes.
o Thus, it is important to find and
target pathways (other than the
already stablished cGAS-STING
pathway) to improve RT efficacy.
o SR1001 (RORα agonist) and
GSK4112 (Rev-erbα agonist) were
identified in a drug screen for IFNb
augmentation.
o Both are involved in the immune
system and the circadian rhythm.
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Fig. 2 Relative mRNA expression for
IFNb1 and CCL5 (downstream of
IFNb1) in radiated and untreated cells.

o The results show that RORα and Rev-erbα work
together with radiation to augment type 1 IFN
production.
o Since both RORα and Rev-erbα are circadian
controlled, they may exist a link between the
circadian rhythm and the immune response to
radiation.
o Future directions will focus on determining if the
time of drug and radiation delivery relative to the
24-hour circadian cycle plays a role in increasing
RT induced anti-tumor immunity.
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